The price-to-earnings ratio for Moderna Inc. (NASDAQ: MRNA) is 39.25x, which is above its average ratio. Moreover, the 36-month beta value for MRNA is 1.62. Analysts have varying opinions on the stock, with 10 analysts rating it as a “buy,” 2 as “overweight,” 10 as “hold,” and 2 as “sell.”
The average price recommended by analysts for Moderna Inc. (MRNA) is $179.31, which is $75.21 above the current market price. The public float for MRNA is 343.79M and currently, short sellers hold a 5.25% of that float. On September 18, 2023, MRNA’s average trading volume was 3.80M shares.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
MRNA) stock’s latest price update
The stock of Moderna Inc. (NASDAQ: MRNA) has decreased by -7.37 when compared to last closing price of 114.59. Despite this, the company has experienced a 0.32% gain in its stock price over the last five trading sessions. The Motley Fool reported 2023-09-18 that Moderna’s coronavirus vaccine revenue is tanking, and it could continue to fall. However, the company has plenty of activity ongoing in the pipeline, with new medicines on the way.
MRNA’s Market Performance
Moderna Inc. (MRNA) has experienced a 0.32% rise in stock performance for the past week, with a -0.09% drop in the past month, and a -17.55% drop in the past quarter. The volatility ratio for the week is 4.55%, and the volatility levels for the past 30 days are at 4.30% for MRNA. The simple moving average for the last 20 days is -4.45% for MRNA stock, with a simple moving average of -26.32% for the last 200 days.
Analysts’ Opinion of MRNA
Many brokerage firms have already submitted their reports for MRNA stocks, with TD Cowen repeating the rating for MRNA by listing it as a “Market Perform.” The predicted price for MRNA in the upcoming period, according to TD Cowen is $125 based on the research report published on August 04, 2023 of the current year 2023.
MRNA Trading at -6.07% from the 50-Day Moving Average
After a stumble in the market that brought MRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.14% of loss for the given period.
Volatility was left at 4.30%, however, over the last 30 days, the volatility rate increased by 4.55%, as shares surge +4.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.46% lower at present.
During the last 5 trading sessions, MRNA rose by +0.60%, which changed the moving average for the period of 200-days by -38.53% in comparison to the 20-day moving average, which settled at $111.32. In addition, Moderna Inc. saw -40.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRNA starting from AFEYAN NOUBAR, who sale 15,000 shares at the price of $109.70 back on Sep 13. After this action, AFEYAN NOUBAR now owns 2,221,931 shares of Moderna Inc., valued at $1,645,522 using the latest closing price.
Klinger Shannon Thyme, the Chief Legal Officer of Moderna Inc., sale 557 shares at $107.22 during a trade that took place back on Sep 08, which means that Klinger Shannon Thyme is holding 7,215 shares at $59,722 based on the most recent closing price.
Stock Fundamentals for MRNA
Current profitability levels for the company are sitting at:
- +48.49 for the present operating margin
- +69.84 for the gross margin
The net margin for Moderna Inc. stands at +43.76. The total capital return value is set at 52.37, while invested capital returns managed to touch 47.81. Equity return is now at value 6.60, with 4.90 for asset returns.
Based on Moderna Inc. (MRNA), the company’s capital structure generated 6.28 points at debt to equity in total, while total debt to capital is 5.90. Total debt to assets is 4.60, with long-term debt to equity ratio resting at 5.25. Finally, the long-term debt to capital ratio is 4.94.
When we switch over and look at the enterprise to sales, we see a ratio of 3.31, with the company’s debt to enterprise value settled at 0.02. The receivables turnover for the company is 7.71 and the total asset turnover is 0.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.73.
Conclusion
To wrap up, the performance of Moderna Inc. (MRNA) has been bad in recent times. The stock has received a bearish of “sell” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
